Clinical Scorecard: ACP, OpenEvidence partner on clinical AI
At a Glance
Category
Detail
Condition
ACP announced a licensing agreement with OpenEvidence to make ACP clinical guidance and Annals of Internal Medicine content available through its AI-enabled clinical decision support platform.
Key Mechanisms
The agreement allows OpenEvidence to license ACP clinical guidelines, guidance statements, practice points, and best practice advice, along with published content from Annals of Internal Medicine.
Target Population
Physicians; internal medicine is the largest specialty represented on OpenEvidence, according to its chief medical officer.
Care Setting
The announcement describes access to clinical guidance and published research at the point of care; it does not specify implementation details or settings.
Key Highlights
ACP announced a licensing agreement with OpenEvidence to make ACP guidance and Annals of Internal Medicine content available through its platform.
Licensed ACP materials include clinical guidelines, guidance statements, practice points, and best practice advice.
Annals of Internal Medicine publishes peer-reviewed original research, reviews, clinical guidelines, and commentary on clinical practice, health care delivery, public health, health policy, medical education, ethics, and research methodology.
The announcement did not provide an implementation timeline or specify which portions of the journal’s content would be available.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
No patient population or prescribing data were reported.
No treatment recommendations or prescribing findings were reported; the announcement concerns access to clinical guidance and research through an AI-enabled platform.
Clinical Best Practices
The announcement describes access to ACP guidance and peer-reviewed content at the point of care; it does not provide clinical practice recommendations.
Review identifies recurring sex-based differences across specialties, including lower use of intensive and guideline-compliant treatment among female patients.
Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
